Ningxia Zhongke Biotechnology Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rui Chen

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Aug 30

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Jul 12

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Jun 03

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Apr 21

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Feb 27

AMMINISTRATORE DELEGATO

Rui Chen (49 yo)

no data

Mandato

CN¥970,000

Compensazione

Mr. Rui Chen serves as General Manager of Ningxia Zhongke Biotechnology Co., Ltd. and served as its Director until July 01, 2022. Mr. Chen served as Chief Financial Officer of Ningxia Zhongke Biotechnology...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Baoqing Shentu	Independent Director	2.3yrs	Nessun dato	Nessun dato
Xiufeng Yue	Independent Director	2.3yrs	Nessun dato	Nessun dato
Can Ting Zhu	Director	2.3yrs	Nessun dato	Nessun dato
Cun Zai Han	Chairman of the Supervisory Board	no data	Nessun dato	Nessun dato
Xu Ran	Supervisor	no data	Nessun dato	Nessun dato
Chao Lin	Director	2.3yrs	Nessun dato	Nessun dato
Yijie Lou	Independent Director	2.3yrs	Nessun dato	Nessun dato
Jiangming Wu	Chairman	2.8yrs	Nessun dato	Nessun dato
Bin Li	Director	2.3yrs	CN¥47.30k	Nessun dato
Yankun Li	Director	2.3yrs	CN¥50.80k	Nessun dato
Chun hai Hu	Director	2.3yrs	Nessun dato	Nessun dato
Xinling Wang	Independent Director	2.3yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

49yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600165 non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Ningxia Zhongke Biotechnology Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.12 loss in 3Q 2023)

Ningxia Zhongke Biotechnology Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024

What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: CN¥0.55 loss per share (vs CN¥0.12 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump

Now 27% overvalued

Ningxia Zhongke Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 15, 2024

Now 24% overvalued

Now 21% overvalued

Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)

Now 23% overvalued

Ningxia Zhongke Biotechnology Co., Ltd(SHSE:600165) dropped from Shanghai Stock Exchange Composite Index

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.68 loss per share (vs CN¥0.21 loss in FY 2022)

Ningxia Zhongke Biotechnology Co., Ltd, Annual General Meeting, May 17, 2024

Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless

Ningxia Zhongke Biotechnology Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024

Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues

Ningxia Zhongke Biotechnology Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released

Ningxia Zhongke Biotechnology Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.046 profit in 2Q 2022)

Ningxia Zhongke Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.034 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released

Ningxia Xinri Hengli Steel Wire Rope Co., Ltd (SHSE:600165) entered into an agreement to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) for CNY 106 million.

Full year 2021 earnings released: CN¥0.034 loss per share (vs CN¥0.031 profit in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.005 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.02 loss per share (vs CN¥0.012 loss in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.031 (vs CN¥0.066 loss in FY 2019)

New 90-day low: CN¥5.82

New 90-day low: CN¥6.71

New 90-day high: CN¥8.42

Third quarter earnings released

Shizuishan Zhengxingcheng New Material Technology Partnership Enterprise (Limited Partnership) agreed to acquire 10% stake in Ningxia Hengli Biological New Material Co., Ltd. from Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd (SHSE:600165).

First half earnings released

First half earnings released

New 90-day high - CN¥8.15

Ningxia Xinri Hengli Steel Wire Rope Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media